Oleolive, Inc.

Shreveport, LA · Biotech · Private

Propentofylline (PPF), a repurposed small-molecule drug that downregulates TROY to sensitize glioblastoma to chemotherapy and radiotherapy

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · oleo.live

Sector: Biotech
Headquarters: Shreveport, LA
Total capital: $5.9M

Federal grants: $5.4M; 12 awards · 2018–2025; Rank in peer group#144 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $550K; 2 awards · Defense; Rank in Biotech#227 of 4373
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Sep 2025Federal grantHealth and Human S · Phase I · Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis$309K
Sep 2023Federal grantHealth and Human S · Phase II · Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease$250K
May 2023Federal grantHealth and Human S · Phase II · Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease$806K
Sep 2022Federal grantHealth and Human S · Phase II · Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease$1.7M
Aug 2022Federal grantHealth and Human S · Phase I · Chemosensitization of Glioblastoma by Propentofylline$400K
May 2021Federal grantHealth and Human S · Phase I · Oleocanthal functional food products for breast cancer recurrence control$55K
Jun 2020Federal contractDefense · COVID-19 Dib Agile-prp Lyophilized Platelet Rich Blood Product$500K

Show 7 earlier federal awards

Jun 2020Federal grantHealth and Human S · Phase I · Oleocanthal functional food products for breast cancer recurrence control$455K
May 2020Federal grantHealth and Human S · Phase I · Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimer’s Disease$103K
May 2020Federal grantDefense · Phase II · Open Call for Innovative Defense-Related Dual-Purpose Technologies/Solutions with a Clear Air Force Stakeholder Need$500K
Sep 2019Federal grantHealth and Human S · Phase I · Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimer’s Disease$450K
Aug 2019Federal contractDefense · Innovative Defense-related Dual-purpose Technologies/solutions$50K
May 2019Federal grantHealth and Human S · Phase I · Evaluation of oral oleocanthal to prevent and/or treat Alzheimer’s disease and related dementias$67K
Sep 2018Federal grantHealth and Human S · Phase I · Evaluation of oral oleocanthal to prevent and/or treat Alzheimer’s disease and related dementias$270K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#144 · top 28%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

ABTERRA BIOSCIENCES, INC.Similar federal contract value in Biotech · $556K in contracts
ALLELE BIOTECHNOLOGY AND PHARMACEUTICALSSimilar federal contract value in Biotech · $550K in contracts
VITAN-BIOTECH LLCSimilar federal contract value in Biotech · $550K in contracts
FERROLOGIX INCSimilar federal contract value in Biotech · $548K in contracts
Hafion Inc.Similar federal contract value in Biotech · $536K in contracts
BrainXell, IncSimilar federal contract value in Biotech · $516K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.